The 2018-2019 trial you mention demonstrated a 40% response rate in 10 relapsed/refractory AML patients after 1 (improperly dosed) single agent RC110 cycle. These results were announced to the market in June 2020.
The 2021-2023 trial (also improperly dosed) with a 40% CR rate in r/r AML failed to elicit any cardiotoxicity despite being used in combination with known cardiotoxic agents.
Both these trials were initiated by a third party prior to the drug's MOA being discovered.
Your understanding of RC110 vs RC220 also leaves a lot to be desired - but happy to discuss this in the appropriate thread.
IMU Price at posting:
3.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)